Kenji Hirotani
Overview
Explore the profile of Kenji Hirotani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamasaki A, Miyake R, Hara Y, Okuno H, Imaida T, Okita K, et al.
Cancer Med
. 2023 Feb;
12(8):9684-9696.
PMID: 36751113
Background: Colorectal cancer (CRC) is the most common malignancy in the world, and novel molecular targeted therapies for CRC have been vigorously pursued. We searched for novel combination therapies based...
2.
Yonesaka K, Tanizaki J, Maenishi O, Haratani K, Kawakami H, Tanaka K, et al.
Clin Cancer Res
. 2021 Dec;
28(2):390-403.
PMID: 34921025
Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated -mutated non-small cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance are limited. HER3 mediates...
3.
Okita K, Okazaki S, Uejima S, Yamada E, Kaminaka H, Kondo M, et al.
Oncotarget
. 2020 Feb;
11(1):31-45.
PMID: 32002122
Resistance of progressive cancers against chemotherapy is a serious clinical problem. In this context, human epidermal growth factor receptor 3 (HER3) can play important roles in drug resistance to HER1-...
4.
Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, et al.
J Clin Invest
. 2019 Oct;
130(1):374-388.
PMID: 31661465
Immunotherapy targeting programmed cell death-1 (PD-1) induces durable antitumor efficacy in many types of cancer. However, such clinical benefit is limited because of the insufficient reinvigoration of antitumor immunity with...
5.
Hashimoto Y, Koyama K, Kamai Y, Hirotani K, Ogitani Y, Zembutsu A, et al.
Clin Cancer Res
. 2019 Sep;
25(23):7151-7161.
PMID: 31471314
Purpose: HER3 is a compelling target for cancer treatment; however, no HER3-targeted therapy is currently clinically available. Here, we produced U3-1402, an anti-HER3 antibody-drug conjugate with a topoisomerase I inhibitor...
6.
Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, et al.
Mol Cancer Ther
. 2019 Aug;
18(11):2043-2050.
PMID: 31395690
HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody-drug conjugate...
7.
Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, et al.
Oncogene
. 2018 Oct;
38(9):1398-1409.
PMID: 30302022
EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3-1402 is an anti-HER3 antibody-drug conjugate with a novel...
8.
Burvenich I, Parakh S, Lee F, Guo N, Liu Z, Gan H, et al.
Theranostics
. 2018 Aug;
8(15):4199-4209.
PMID: 30128047
B7-H3 is a transmembrane protein widely expressed in a variety of cancers and has been shown to play a role in anti-tumor immunity. This study aims to develop a molecular...
9.
Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, et al.
Clin Cancer Res
. 2018 Mar;
24(11):2653-2664.
PMID: 29530936
Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non-small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed in various...
10.
Bandyopadhyay A, Favours E, Phelps D, Pozo V, Ghilu S, Kurmashev D, et al.
Pediatr Blood Cancer
. 2017 Oct;
65(2).
PMID: 29080385
Background: Integrating molecularly targeted agents with cytotoxic drugs used in curative treatment of pediatric cancers is complex. An evaluation was undertaken with the ERBB3/Her3-specific antibody patritumab (P) either alone or...